DEF: Claritev Corporation Seeks Stockholder Approval for Incentive Plan Amendment

Claritev Corporation is asking stockholders to approve an amendment to its 2020 Omnibus Incentive Plan to increase the number of shares available for grant.

Summary

• Claritev Corporation is seeking stockholder approval to amend its 2020 Omnibus Incentive Plan to increase the number of shares available for grant by 1,750,000, bringing the total to 5,396,250 shares.
• The company believes this increase is crucial for attracting, motivating, and retaining qualified personnel and aligning their interests with those of stockholders.
• The board approved the amendment on February 20, 2025, contingent upon stockholder approval.
• If approved, the amendment will take effect immediately; otherwise, the plan will continue in its current form until the existing share reserve is exhausted.
• As of March 7, 2025, there were 304,851 shares remaining available for issuance under the plan.
• The amendment aims to manage equity compensation needs for the next 12 to 24 months.
• The dilutive effect of the share reserve increase is estimated at 8.5%, with a total potential dilution of 18.4% including outstanding awards.
• The three-year average burn rate is 5.3%.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's excitement about the company's transformation and future vision, the financial results for 2024 were below expectations, indicating some challenges.

Positives

• The amendment is expected to help Claritev attract and retain key employees.
• Equity incentives align employee interests with those of stockholders.
• The plan includes good corporate governance practices, such as requiring stockholder approval for repricing options.
• The company is focused on long-term growth and creating stockholder value.

Negatives

• The share reserve increase will dilute existing stockholders' equity.
• The company's financial results in 2024 were below expectations, with revenue decreasing by 3.2% from 2023.

Risks

• If stockholders do not approve the amendment, the company's ability to offer competitive equity incentives may be limited.
• The company faces risks related to cybersecurity, information security, artificial intelligence, and data privacy.

Future Outlook

The company is embarking on a multi-year transformation to serve the entire healthcare continuum, aiming to impact cost, transparency, and quality and diversify its business through new product innovation and development.

Management Comments

• Travis Dalton, Chairman of the Board, President and Chief Executive Officer: 'We've laid the foundation to achieve our vision of becoming a technology and data insights company focused on affordability, transparency and quality across the healthcare ecosystem.'
• Travis Dalton: 'This year is the year of The Turn for Claritev.'
• Travis Dalton: 'Were moving fast, and were not slowing down.'

Industry Context

Claritev operates in the healthcare technology, data, and insights industry, focusing on affordability, transparency, and quality in the U.S. healthcare system. The company's platform sits at the nexus of payors, employers/plan sponsors, healthcare providers, and their patients.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• The document mentions a peer group of companies used for benchmarking executive compensation, including ACI Worldwide, Broadridge Financial Solutions, Clarivate Plc, Concentrix Corporation, CSG Systems International, Evolent Health, Fair Isaac Corporation, HealthEquity, Maximus, Premier, R1 RCM Inc., Veeva Systems Inc., Veradigm Inc., and WEX Inc.

Management Changes

Related Party Transactions

• Claritev obtained insurance policies through Hub International Limited, an affiliate of Hellman & Friedman LLC, paying approximately $1.0 million in payments and commissions.

Stakeholder Impact

• The company aims to make healthcare more transparent, fair, and affordable for all stakeholders, including payors, employers, patients, providers, and third parties.
• The company's services identified $24.7 billion in potential medical cost savings for clients, health plan sponsors, and members in 2024.

Next Steps

• Stockholders will vote on the election of directors, ratification of the independent registered public accounting firm, advisory vote on executive compensation, and approval of the amendment to the Claritev Corporation 2020 Omnibus Incentive Plan at the Annual Meeting on April 30, 2025.

Key Dates

Keywords

incentive plan, equity compensation, stock options, restricted stock units, share reserve, dilution, burn rate, executive compensation, corporate governance, Claritev